spacer
home > ict > winter 2018 > clinical complexities
PUBLICATIONS
International Clinical Trials

Clinical Complexities

Industry-wide, clinical trials are becoming vastly more complicated and costly as investigational therapies develop in sophistication, and the amount of data needed not only for regulatory approval, but also for commercial success (ie, market access and adoption), expands exponentially.

Rising complexity is particularly acute in central nervous system (CNS) clinical trials, where industry-wide challenges are compounded by the unique intricacies associated with research in neurologic, analgesic, and psychiatric disorders. It continues to rise at a big cost. According to a 2014 report from the Tufts Center for the Study of Drug Development, the overall clinical approval success rate for CNS compounds from 1995 to 2007 was just 6.2% and less than half the 13.3% rate for non-CNS drugs (1).

CNS clinical trials are difficult and becoming more so because, in large part, the understanding of neurobiology is incomplete and the pathology of many CNS disorders is unknown. Many endpoints used in CNS studies – eg, pain, mood, or cognitive improvement or decline – are inherently subjective, and signal detection is more difficult in the absence of objective measures for diagnosis and treatment response. Novel and objective study endpoints are being explored, and assessment tools are becoming more sensitive – but also are more difficult to administer without proper training. Newer, targeted drug delivery methods, such as those involving ultrasonography, may require patient adherence to a comprehensive set of procedures, compounding the already significant problem of adherence in CNS clinical trials. Moreover, the placebo response is high in CNS trials; new, more complex study designs are being employed in the effort to minimise this, often increasing the burden on clinical sites. Advances in technology capable of facilitating real-time monitoring and measurement – and eventually even ‘site-less’ clinical trials – are starting to make inroads into CNS study design and implementation while also raising the stakes for scientific rigor and technological know-how.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tom Zoda is Executive Vice President and General Manager, Clinical Development, CNS, for Syneos Health. Syneos Health, created through the merger of two industry leading companies – INC Research and inVentiv Health – is the only fully integrated end-to-end biopharmaceutical solutions organisation and is purpose-built to accelerate customer performance to address modern market realities.
spacer
Tom Zoda
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Foundation Announces Support For New Open Collaborative Platform to Accelerate the Development of Plant-Based Foods

A new collaborative platform, Plant2Food, aims to accelerate the development of plant-based foods. Researchers and companies are invited to collaborate in exploring complex challenges within plant and food science and sharing new knowledge across sectors – without taking out patents based on the results. The Novo Nordisk Foundation is supporting the platform with up to €27 million over the next five years.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement